Litigation Details for AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
✉ Email this page to a colleague
AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
| Docket | 1:24-cv-00551 | Date Filed | 2024-05-06 |
| Court | District Court, D. Delaware | Date Terminated | 2025-07-29 |
| Cause | 35:1 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,919,598; 8,501,698; 8,685,934; 9,616,028 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Apotex Inc.
Details for AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-05-06 | External link to document | |||
| 2024-05-06 | 16 | Brief - Opening Brief in Support | for any of U.S. Patent Nos. 7,919,598 (“the ’598 patent”), 8,501,698 (“the ’698 patent”), 8,685,934 (“…(“the ’934 patent”), and 9,616,028 (“the ’028 patent) (collectively, the “Patents-in-Suit”), does not… 35 U.S.C. §§ 102 or 103 for the ’598 and ’698 patents. Thus, even if Apotex’s proposed reliance on its… PageID #: 262 construed claim of the ’598 patent.”) (emphases added)), cannot be maintained as Apotex…expiration of AstraZeneca’s Orange Book-listed Patents-in-Suit. The filing of an ANDA is a statutory | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
